Oct 21, 2014, 00:00
by
Michael Croft
CHAPEL HILL, NC, UNITED STATES - Oct 21, 2014 - Rho, a contract research organization (CRO) providing clinical research services in both the commercial and federal market, has been awarded the renewal of their existing federal contract with the National Institute of Dental and Craniofacial Research (NIDCR)
CRO to provide comprehensive clinical
research management and support
CHAPEL HILL, NC, UNITED STATES - Oct 21, 2014 - Rho, a contract
research organization (CRO) providing clinical research services in
both the commercial and federal market, has been awarded the
renewal of their existing federal contract with the National
Institute of Dental and Craniofacial Research (NIDCR). The NC-based
CRO will provide clinical research operations and management
support (CROMS) to the NIDCR and to NIDCR funded clinical research
studies from study preparation and initiation through study
completion and close-out.
The $4.2 million one year contract includes four one-year
options with a total estimated ceiling of $21.9 million.
We are excited to support NIDCRs research divisions and
continue building the infrastructure for groundbreaking studies of
oral, dental and craniofacial diseases and disorders, said Laura
Helms Reece, Dr. P.H., Chief Executive Officer for Rho. Rhos
expertise and resources will help assure top-notch study design and
execution, data management, statistical analysis, and regulatory
compliance.
Dr. Nancy Yovetich and Ms. Cathie Snyder will continue their
leadership roles on the renewed contract as the Principal
Investigator and Program Director, respectively. Through the
contract period, Rho will operate and maintain a state-of-the-art
secure computer-based system for the collection, management,
storage, and quality control of clinical data, for studies
supported by NIDCR. Rho will provide study support services such as
protocol development; study startup planning; clinical
research-related training; quality management support; management
of or consulting for study implementation; technical and
administrative support; website design and maintenance; review and
submission of regulatory documents for Investigational New Drug
(IND) and Investigational Device Exemptions (IDE) applications;
statistical analysis; and manuscript collaboration. Additionally,
Rho will design, develop, implement, and maintain an Adverse
Event/Serious Adverse Event (AE/SAE) reporting system that will
constitute NIDCRs Pharmacovigilance Program.
As the NIDCR-CROMS contractor since 2008, Rho has previously
provided similar support for hundreds of NIDCR studies. For
additional details about Rhos CROMS program, visit www.rhoworld.com/rho/federal-research.
This project has been funded in whole or in part with Federal
funds from the National Institute of Dental and Craniofacial
Research (administered by the National Heart, Lung, and Blood
Institute), National Institutes of Health, Department of Health and
Human Services, under Contract No. HHSN268201400073C.
For more information about the National Institute of Dental and
Craniofacial Research visit www.nidcr.nih.gov.
Media: For more information, contact Bernadette
Miller of Largemouth Communications at bernadette@largemouthpr.com
and (703) 297-5992.
About Rho
Rho, a privately-held, contract research organization (CRO)
located in Chapel Hill, NC, provides a full range of clinical
research services across the entire drug development process. For
30 years, Rho has been a trusted partner to some of the industrys
leading pharmaceutical, biotechnology, and medical device companies
as well as academic and government organizations. Our commitment to
excellence, our innovative technologies, and our therapeutic
expertise accelerate time to market, maximize returns on
investment, and lead to an exceptional customer experience. For
more information, please visit www.rhoworld.com and follow us on
Twitter.
# # #